AKT1 and prostate cancer: In PC-3 tumor xenograft models, AMD3100 has been shown to inhibit tumor growth and reduce microvessel formation by inhibiting CXCR4/Akt signal transduction [55], and CTCE-9908 has been shown to reduce tumor spread and angiogenesis in an orthotopic prostate cancer model [56].